NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has announced that it will release its second quarter and year to date 2024 financial results on August 14, 2024, after market close. The results will be available via press release on the company's investor relations website.
Following the release, NRx Pharmaceuticals will host a conference call at 4:30 PM ET on the same day to discuss the financial results and provide a corporate update. Investors can access the call through a live webcast on the company's website or by dialing in using the provided domestic and international phone numbers.
Positive
- None.
Negative
- None.
News Market Reaction – NRXP
In the trading session that priced this news, NRXP declined 2.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events . Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-and-year-to-date-2024-financial-results-on-august-14-2024-302221376.html
SOURCE NRx Pharmaceuticals, Inc.